Abstract
Regulatory T cells (Tregs) play an important role in anti-cancer response. Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is a molecule expressed on T lymphocytes which is capable to down-regulate cytotoxic T cells and is constitutively expressed on Tregs. Little is known about the lung population of Tregs bearing CTLA-4 in lung cancer. There are two forms of CTLA-4 expression: on the cell surface after activation (s), and intracellularly as a storage (in). We previously presented the difference between s and in expression of CTLA-4 on peripheral blood (PB) lymphocytes. The aim of study was to compare the proportion of Tregs and expression of CTLA-4 on Tregs in bronchoalveolar lavage fluid (BALF) with PB of patients with lung cancer. 17 lung cancer patients (confirmed primary adenocarcinoma) were investigated. Flow cytometry method with two panels of monoclonal antibodies CD4⁄CD25⁄CD127/FoxP3/CTLA-4 and CD3/CD16+CD56/CD45/CD4/CD19/CD8 for lymphocyte subpopulations were used in BALF and PB. We observed significantly higher proportion of Tregs in BALF than in PB (median value: 12 vs. 6.1%, p We supported the significant role of Tregs with expression of CTLA-4 in the regulation of local vs. systemic responses and the usefulness of BALF analysis in evaluation of local immune status in lung cancer patients. It may have therapeutic relevance in individual indication for anti-CTLA 4 therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
